FeesSafety
Pluang+

Investigation launched into LENZ Therapeutics over possible securities fraud after weak sales report.

Market News
01 Oct 2026, 17:00 WIB
PRNewsWire
View Source
Bearish
Investigation launched into LENZ Therapeutics over possible securities fraud after weak sales report.

LENZ Therapeutics reported weaker-than-expected Q2 2026 results, with flat organic sales for its eye drop product VIZZ and revenue mainly from one-time licensing deals. Following this, Bank of America downgraded LENZ stock and cut its price target sharply, causing the stock to drop. Pomerantz LLP is now investigating whether LENZ and its executives engaged in securities fraud or unlawful practices, potentially impacting investors. This investigation could lead to legal action and compensation claims for affected shareholders.

LENZ Therapeutics and its recent legal scrutiny provide context for health sector performance on Pluang. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 20:52 WIB: Of 100 priced health-sector US stocks, 30 rose and 67 fell today. Notable movers include CAH (Cardinal Health Inc) at USD 231.18 with a 1-day change of +4.14% and 100% buy order activity, TLRY (Tilray Brands Inc) at USD 3.61 with a 1-day change of -3.73% and 99% sell order activity, and CTXR (Citius Pharmaceuticals Inc) at USD 0.55 with a 1-day change of +3.58% and 66% sell order activity.

More News

Ferrari shows strong profits and brand exclusivity; Rivian grows fast but faces losses and risks.

Ferrari shows strong profits and brand exclusivity; Rivian grows fast but faces losses and risks.

Ferrari maintains high profitability by limiting production and preserving brand exclusivity, generating $8.2 billion revenue and $1.8 billion net income with a 22% margin in the past year. Rivian, focused on expanding electric vehicle production and...

Market News
Neutral
1 hour ago
Top 10 stock picks revealed with 794% average return vs. S&P 500's 203%.

Top 10 stock picks revealed with 794% average return vs. S&P 500's 203%.

Stock Advisor's analyst team has identified the 10 best stocks to buy right now, boasting an impressive total average return of 794%, far outperforming the S&P 500's 203% return. This insight offers investors a strong opportunity to potentially maxim...

Bullish
1 hour ago
Stock valuations are high by some metrics but not clear signals of a market drop.

Stock valuations are high by some metrics but not clear signals of a market drop.

The Shiller CAPE ratio and Buffett indicator show U.S. stocks are historically expensive, with CAPE at 40 and Buffett indicator near 250%, levels seen only during major past market peaks. However, other measures like the forward P/E ratio suggest mor...

Neutral
1 hour ago
Berkshire Hathaway's insurance profits dip in Q3 amid rising claims and lower interest rates.

Berkshire Hathaway's insurance profits dip in Q3 amid rising claims and lower interest rates.

Berkshire Hathaway's insurance segment, a major profit contributor, saw a decline in Q3 earnings due to increased claims, higher broker commissions, and more advertising costs at GEICO. Additionally, lower interest rates reduced investment income fro...

Company Fundamentals
Bearish
1 hour ago
Anthropic's $120B deal with SpaceX boosts merger talks with Tesla and AI infrastructure bets.

Anthropic's $120B deal with SpaceX boosts merger talks with Tesla and AI infrastructure bets.

Anthropic plans to spend up to $120.5 billion with SpaceX's AI-focused subsidiary through 2029, paying about $3.1 billion monthly starting December. This deal supports SpaceX's AI infrastructure investments and strengthens its financial position ahea...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App